Research ArticleArticle
The Impact of Solute Carrier (SLC) Drug Uptake Transporter Loss in Human and Rat Cryopreserved Hepatocytes on Clearance Predictions
Patrik Lundquist, Johan Lööf, Anna-Karin Sohlenius-Sternbeck, Eva Floby, Jenny Johansson, Johan Bylund, Janet Hoogstraate, Lovisa Afzelius and Tommy B. Andersson
Drug Metabolism and Disposition March 2014, 42 (3) 469-480; DOI: https://doi.org/10.1124/dmd.113.054676
Patrik Lundquist
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
Johan Lööf
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
Anna-Karin Sohlenius-Sternbeck
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
Eva Floby
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
Jenny Johansson
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
Johan Bylund
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
Janet Hoogstraate
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
Lovisa Afzelius
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
Tommy B. Andersson
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Drug Uptake Transporters in Cryopreserved Hepatocytes
Patrik Lundquist, Johan Lööf, Anna-Karin Sohlenius-Sternbeck, Eva Floby, Jenny Johansson, Johan Bylund, Janet Hoogstraate, Lovisa Afzelius and Tommy B. Andersson
Drug Metabolism and Disposition March 1, 2014, 42 (3) 469-480; DOI: https://doi.org/10.1124/dmd.113.054676
Research ArticleArticle
Drug Uptake Transporters in Cryopreserved Hepatocytes
Patrik Lundquist, Johan Lööf, Anna-Karin Sohlenius-Sternbeck, Eva Floby, Jenny Johansson, Johan Bylund, Janet Hoogstraate, Lovisa Afzelius and Tommy B. Andersson
Drug Metabolism and Disposition March 1, 2014, 42 (3) 469-480; DOI: https://doi.org/10.1124/dmd.113.054676
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement